
Big pharma companies have become more measured in their risk taking, with mergers and acquisitions gradually giving way to joint ventures and partnerships.

Big pharma companies have become more measured in their risk taking, with mergers and acquisitions gradually giving way to joint ventures and partnerships.

AI-based technologies are increasingly being used for things such as virtual screening, physics-based biological activity assessment, and drug crystal-structure prediction.

Last year, the majority of new drug approvals were for small molecules, including treatments for HIV, cancer, infections, heart and kidney disease, and neurological disorders.

Published: January 5th 2023 | Updated: